No Data
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $37
Monopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson's Disease Treatment
Monopar Therapeutics Analyst Ratings
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $22
Transformative Licensing Acquisition Drives Buy Rating for Monopar Therapeutics
Express News | Monopar Therapeutics Inc. : H.c. Wainwright Raises Target Price to $22 From $6
No Data
No Data